ArticleScientific reports2026
CEP72 promotes malignant progression and shapes the tumor immune microenvironment in hepatocellular carcinoma: integrated multi-cohort bioinformatics and in vitro validation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) benefit only a subset of patients with hepatocellular carcinoma (HCC), and biomarkers linking ICI response with tumor biology remain limited. We investigated CEP72 as an ICI-response–associated gene and evaluated its prognostic, immune, and functional relevance in HCC. Anti–PD-1 response–associated differentially expressed genes (DEGs) were identified in GSE35640 and screened for prognostic relevance in TCGA-LIHC using univariate Cox models for overall survival (OS), disease-specific survival (DSS), and progression-free interval (PFI). Intersected prognostic genes were used to construct and validate multigene survival models across TCGA-LIHC and independent cohorts. CEP72 was prioritized for pathway activity (GSVA/GSEA), tumor microenvironment deconvolution, validation in independent immunotherapy cohorts, drug sensitivity association (GDSC), and single-cell localization in HCC (TISCH2). CEP72 was silenced with two siRNAs followed by qPCR, CCK-8, colony formation, and wound-healing assays, and protein expression was assessed by immunohistochemistry. Of 209 anti–PD-1–associated DEGs, 25 were consistently prognostic for OS/DSS/PFI, and 23 were dysregulated between tumor and adjacent liver. A Ridge-based signature showed stable discrimination (mean AUC ~ 0.66) and stratified survival across cohorts, supported by meta-analysis (pooled HR 1.84, 95% CI 1.21–2.78). CEP72 was upregulated in HCC and associated with proliferative programs (cell cycle and DNA damage/repair), higher PI3K activity, and distinct immune infiltration patterns. Higher CEP72 expression was associated with ICI response and predicted sensitivity to multiple targeted agents. Single-cell analyses localized CEP72 predominantly to malignant/epithelial compartments. Functionally, CEP72 knockdown reduced proliferation, clonogenicity, and migration, while increasing apoptosis. CEP72 integrates prognostic stratification with tumor-intrinsic oncogenic programs and immune/therapeutic response signals, supporting CEP72 as a candidate biomarker and potential vulnerability in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.